The FDA warned consumers and the medical community this week about the risk of muscle damage and rhabdomyolysis from highest doses of the cholesterol drug simvastatin. The lawyers at Saiontz & Kirk, P.A. are reviewing potential Zocor lawsuits for individuals who have been diagnosed with rhabdomyolysis, myopathy, kidney damage or a muscle injury.


According to a drug safety communication about potential Zocor side effects issued on June 8, the FDA is recommending limited use of 80 mg simvastatin doses due to the increased risk of muscle damage:

Patients taking simvastatin 80 mg daily have an increased risk of myopathy compared to patients taking lower doses of this drug or other drugs in the same class. The risk appears to be higher during the first year of treatment, is often the result of interactions with certain medicines, and is frequently associated with a genetic predisposition toward simvastating-related myopathy.

Myopathy is a muscle disease which can result in muscle pain, tenderness, weakness or an elevation of muscle enzyme in the blood (reatine kinase or CK). The most serious form of myopathy from Zocor can lead to rhabdomyolysis, which could cause serious and potentially life-threatening kidney damage or kidney failure.


The Zocor lawyers at Saiontz & Kirk, P.A. are reviewing potential lawsuits for individuals who have taken high doses of Zocor, generic simvastatin or other drugs containing the medication, including Vytorin and Simcor. Compensation may be available for individuals diagnosed with:

  • Rhabdomyolysis
  • Myopathy
  • Kidney Damage
  • Kidney Failure
  • Other Muscle Tissue Problems

All cases are being pursued under a contingency fee agreement, which means that there are no attorney fees unless a recovery for a Zocor muscle injury is obtained. To review a potential Zocor rhabdomyolysis lawsuit for yourself, a friend or family member, request a free consultation and claim evaluation.